Adipose-derived stromal cells: Their identity and uses in clinical trials, an update.
Adipose-derived stromal cells: Their identity and uses in clinical trials, an update.
复制标题
DOI：
10.4252/wjsc.v3.i4.25
复制
发表时间：
2011-04-26
影响因子：
4.1
通讯作者：
Cousin, Beatrice
中科院分区：
文献类型：
--
作者：
Casteilla, Louis;Planat-Benard, Valerie;Cousin, Beatrice
在成年人中，脂肪组织是丰富的，可以很容易地使用抽脂取样。它与肥胖和相关的代谢紊乱密切相关，现在被描述为未成熟基质细胞的储存库。这些细胞称为脂肪源性基质细胞（ADSC），必须与脂肪组织消化后获得的粗基质血管组分（SVF）区分开来。ADSC与骨髓间充质干细胞有许多共同的特征，包括旁分泌活性，但它们也显示出一些特定的特征，包括更大的血管生成潜力。它们的血管生成特性以及它们的旁分泌活性表明ADSC具有推定的肿瘤促进作用，尽管在这个问题上发表了相互矛盾的数据。SVF细胞和ADSC目前都在几个领域（慢性炎症、缺血性疾病等）的临床试验中进行研究。除了治疗瘘管病的第三阶段试验外，其中大多数试验处于第一阶段，使用自体细胞。 在不久的将来，这些试验的最终结果应该会提供大量关于ADSC使用安全性的数据。
In adults, adipose tissue is abundant and can be easily sampled using liposuction. Largely involved in obesity and associated metabolic disorders, it is now described as a reservoir of immature stromal cells. These cells, called adipose-derived stromal cells (ADSCs) must be distinguished from the crude stromal vascular fraction (SVF) obtained after digestion of adipose tissue. ADSCs share many features with mesenchymal stem cells derived from bone marrow, including paracrine activity, but they also display some specific features, including a greater angiogenic potential. Their angiogenic properties as well as their paracrine activity suggest a putative tumor-promoting role for ADSCs although contradictory data have been published on this issue. Both SVF cells and ADSCs are currently being investigated in clinical trials in several fields (chronic inflammation, ischemic diseases, etc.). Apart from a phase III trial on the treatment of fistula, most of these are in phase I and use autologous cells. In the near future, the end results of these trials should provide a great deal of data on the safety of ADSC use.